Market News

Taconic Capital Advisors LP Trimmed Its Humana (HUM) Position; Macrogenics (MGNX) Sentiment Is 1.58

Taconic Capital Advisors Lp decreased Humana Inc (HUM) stake by 80% reported in 2017Q2 SEC filing. Taconic Capital Advisors Lp sold 20,000 shares as Humana Inc (HUM)’s stock rose 11.38%. The Taconic Capital Advisors Lp holds 5,000 shares with $1.20M value, down from 25,000 last quarter. Humana Inc now has $35.86B valuation. The stock decreased 0.79% or $2 during the last trading session, reaching $251.03. About 188,124 shares traded. Humana Inc. (NYSE:HUM) has risen 35.38% since December 12, 2016 and is uptrending. It has outperformed by 18.68% the S&P500.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company has market cap of $683.06 million. The companyÂ’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It currently has negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

Investors sentiment increased to 1.21 in Q2 2017. Its up 0.01, from 1.2 in 2017Q1. It improved, as 45 investors sold HUM shares while 181 reduced holdings. 84 funds opened positions while 187 raised stakes. 134.86 million shares or 3.43% less from 139.64 million shares in 2017Q1 were reported. Regent Invest Mgmt Lc accumulated 1,819 shares or 0.15% of the stock. Twin Inc has invested 0.18% in Humana Inc. (NYSE:HUM). Commerce National Bank & Trust has 3,899 shares for 0.01% of their portfolio. Delta Asset Mngmt Limited Liability Tn accumulated 0% or 8 shares. Mackenzie Financial reported 6,410 shares. 18,000 were accumulated by Bp Pcl. Evercore Wealth Limited Liability holds 0% of its portfolio in Humana Inc. (NYSE:HUM) for 387 shares. Architects, a New Jersey-based fund reported 234 shares. 432,344 are owned by Sumitomo Mitsui. State Treasurer State Of Michigan invested in 0.09% or 47,426 shares. Schwab Charles Inv Mngmt stated it has 0.15% in Humana Inc. (NYSE:HUM). Marco Limited Liability Corporation accumulated 2,400 shares. Cibc Ww Markets accumulated 20,394 shares or 0.05% of the stock. Korea Corp invested 0.22% in Humana Inc. (NYSE:HUM). Fdx Advisors has 0.01% invested in Humana Inc. (NYSE:HUM).

Analysts await Humana Inc. (NYSE:HUM) to report earnings on February, 14. They expect $2.01 earnings per share, down 3.83% or $0.08 from last year’s $2.09 per share. HUM’s profit will be $287.15 million for 31.22 P/E if the $2.01 EPS becomes a reality. After $3.39 actual earnings per share reported by Humana Inc. for the previous quarter, Wall Street now forecasts -40.71% negative EPS growth.

Among 22 analysts covering Humana (NYSE:HUM), 12 have Buy rating, 0 Sell and 10 Hold. Therefore 55% are positive. Humana had 64 analyst reports since July 30, 2015 according to SRatingsIntel. On Tuesday, January 24 the stock rating was downgraded by Stifel Nicolaus to “Hold”. The rating was maintained by Credit Suisse with “Buy” on Thursday, August 3. RBC Capital Markets maintained the stock with “Sector Perform” rating in Monday, November 9 report. The firm earned “Outperform” rating on Friday, November 11 by Credit Suisse. RBC Capital Markets maintained Humana Inc. (NYSE:HUM) on Tuesday, September 8 with “Sector Perform” rating. The firm has “Buy” rating by Piper Jaffray given on Thursday, July 13. Deutsche Bank maintained it with “Hold” rating and $243 target in Monday, August 7 report. The stock of Humana Inc. (NYSE:HUM) earned “Hold” rating by Cantor Fitzgerald on Tuesday, September 19. The firm earned “Hold” rating on Thursday, November 9 by RBC Capital Markets. The firm earned “Hold” rating on Friday, October 13 by Jefferies.

Analysts await MacroGenics, Inc. (NASDAQ:MGNX) to report earnings on February, 27. They expect $1.48 earnings per share, up 248.00% or $2.48 from last year’s $-1 per share. MGNX’s profit will be $54.50M for 3.13 P/E if the $1.48 EPS becomes a reality. After $-1.28 actual earnings per share reported by MacroGenics, Inc. for the previous quarter, Wall Street now forecasts -215.63% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *